Metformin-Clinical Pharmacology in PCOs • JML Journal of Medicine and Life

2015, Volume 8, Issue 2, pp 187 – 192

Metformin-Clinical Pharmacology in PCOs

Issues

Special Issues

Authors and Affiliations

Dumitrescu R ^{* ***}

Mehedintu C ^{* **}

Briceag I ^***

Purcărea VL ^*

Hudita D ^*

* *“Carol Davila” University of Medicine and Pharmacy, Bucharest, Romania

** **Gynecology Department, “Nicolae Malaxa Hospital”, Bucharest, Romania

*** ***Gynecology Department, “Dr. I. Cantacuzino Hospital”, Bucharest, Romania

Correspondence to:Ruxandra Dumitrescu, MD, Gynecology Department “Dr. I. Cantacuzino Hospital”, 5-7 Ion Movila Street, Bucharest , Romania Mobile phone: +40 722 703 903, E-mail: ruxidum2004@gmail.com

Abstract

Oligo-anovulation, hyperandrogenism and insulin resistance characterizes polycystic ovary syndrome (PCOs). Metformin is the oldest insulin sensitizer used in the management of type 2 diabetes mellitus. In PCOs, metformin decreases the serum lipids, androgen and insulin; induces ovulation and regular menstrual cycle; increases the pregnancy rate.

Keywords

PCOsinfertilitymetformindiabetes mellitusinsulin resistance

Preview

JMedLife-08-187

Download PDF

About this article

PMC ID: 4392089
PubMed ID: 25866577
DOI:

Article Publishing Date (print): Apr-Jun 2015
Available Online:

Journal information

ISSN Printing: 1844-122X
ISSN Online: 1844-3117
Journal Title: Journal of Medicine and Life

Copyright License: Open Access

This article is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use and redistribution provided that the original author and source are credited.